Why advancing is key The goal of oral drug technologies is to beat GLP1s' fragility in the digestive tract, potentially replacing injections for many patients by improving convenience and adherence
Leveraging our expertise in the food industry, we provide insights into the GLP-1 market and consumer spending trends, offering guidance, especially for F&B brands and retailers, on how to navigate this evolving landscape
Along with trademark issues and misleading marketing, Lilly, Novo Nordisk & their suite of lawyers are not fans of compounding either
[DOI] [PMC free article] [PubMed] [Google Scholar] 54.Burmeister MA, Brown JD, Ayala JE, Stoffers DA, Sandoval DA, Seeley RJ, et al
Smaller infarct areas were observed in hearts treated with GLP-1(2836) or GLP-1 (positive controls) as compared with hearts treated with saline or scrambled(2836) (Scram) (negative controls)
However, currently, only Wegovy and Saxenda have been approved for the treatment of obesity, so the market is still in its early stages
